Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

European Journal of Clinical Pharmacology

Volumn 67, Issue SUPPL. 1, 2011, Pages

  Bellanti, Francesco ^a   Kågedal, Bertil ^c   Della Pasqua, Oscar ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cytotoxic drugs; Modelling simulation; Neuroblastoma; Pharmacogenetics; Pharmacokinetics; PKPD modelling

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; APREPITANT; BMS 536924; BMS 690514; CISPLATIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOTOXIC AGENT; DOXORUBICIN; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 90; IMATINIB; IRINOTECAN; MELPHALAN; NEUROKININ 1 RECEPTOR; NUTLIN 3; ONCOLYTIC VIRUS; ORNITHINE DECARBOXYLASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; TANESPIMYCIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; CANCER RESISTANCE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IC 50; NEUROBLASTOMA; NEUROBLASTOMA CELL; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; NEUROBLASTOMA; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT FAILURE;

EID: 79955571945     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0966-3     Document Type: Review

References (157)

1. Maris JM, Hogarty MD, Bagatell R et al (2007) Neuroblastoma. Lancet 369:2106-2120 (Pubitemid 46935947)
2. Maris JM (2005) The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 17:7-13
3. Park JR, Eggert A, Caron H (2008) Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin N Am 55:97-120, x
4. Schramm A, Schulte JH, Klein-Hitpass L et al (2005) Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24:7902-7912 (Pubitemid 41715196)
5. Mora J, Gerald WL, Cheung NK (2003) Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 197:119-124 (Pubitemid 36860000)
6. Castel V, Grau E, Noguera R et al (2007) Molecular biology of neuroblastoma. Clin Transl Oncol 9:478-483
7. Fischer M, Spitz R, Oberthur A et al (2008) Risk estimation of neuroblastoma patients using molecular markers. Klin Pädiatr 220:137-146
8. Krekels EH, van den Anker JN, Baiardi P et al (2007) Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 8:1787-1799 (Pubitemid 47316143)
9. Pruthi S, Boughey JC, Brandt KR et al (2007) A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc 82:1131-1140 (Pubitemid 47357147)
10. Yan L, Hsu K, Beckman RA (2008) Antibody-based therapy for solid tumors. Cancer J 14:178-183
11. Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521-590 (Pubitemid 44403684)
12. Hedgecoe A, Martin P (2003) The drugs don't work: expectations and the shaping of pharmacogenetics. Soc Stud Sci 33:327-364 (Pubitemid 37340838)
13. Groninger E, Meeuwsen-de Boer T, Koopmans P et al (2005) Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer 41:98-103 (Pubitemid 40029662)
14. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P et al (1999) Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 44:203-209 (Pubitemid 29350175)
15. Frost BM, Lonnerholm G, Koopmans P et al (2003) Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 92:551-557 (Pubitemid 37088699)
16. De Bernardi B, Nicolas B, Boni L et al (2003) Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21:1592-1601 (Pubitemid 46594114)
17. Groninger E, Meeuwsen-de Boar T, Koopmans P et al (2002) Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 52:113-118 (Pubitemid 34665960)
18. Lonnerholm G, Frost BM, Abrahamsson J et al (2008) Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 142:616-621 (Pubitemid 352020218)
19. Kushner BH, Kramer K, LaQuaglia MP et al (2004) Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 22:4888-4892 (Pubitemid 46638612)
20. Coze C, Hartmann O, Michon J et al (1997) NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol 15:3433-3440 (Pubitemid 27527714)
21. Garaventa A, Luksch R, Biasotti S et al (2003) A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 98:2488-2494 (Pubitemid 37466665)
22. Valteau-Couanet D, Michon J, Boneu A et al (2005) Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 23:532-540 (Pubitemid 46224230)
23. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG et al (2006) Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47:183-193 (Pubitemid 44025251)
24. Mastrangelo R, Tornesello A, Lasorella A et al (1997) Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 31:153-158 (Pubitemid 27077722)
25. Souid AK, Dubowy RL, Blaney SM et al (2003) Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res 9:703-710 (Pubitemid 36182603)
26. Kushner BH, Budnick A, Kramer K et al (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417-422 (Pubitemid 44036572)
27. Kaneko M, Tsuchida Y, Mugishima H et al (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613-621 (Pubitemid 35285099)
28. Nath CE, Shaw PJ, Montgomery K et al (2005) Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 59:314-324 (Pubitemid 40388087)
29. Nath CE, Shaw PJ, Montgomery K et al (2007) Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 64:151-164 (Pubitemid 47063242)
30. Vassal G, Tranchand B, Valteau-Couanet D et al (2001) Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 27:471-477 (Pubitemid 32266496)
31. Nieto Y, Vaughan WP (2004) Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 33:259-269 (Pubitemid 38256557)
32. Canete A, Gerrard M, Rubie H et al (2009) Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma experience. J Clin Oncol 27:1014-1019
33. Diaz MA, Vicent MG, Madero L (1999) High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 24:1157-1159 (Pubitemid 30021206)
34. Hartmann O, Valteau-Couanet D, Benhamou E et al (1997) Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 33:2126-2129 (Pubitemid 28123469)
35. Pritchard J, Cotterill SJ, Germond SM et al (2005) High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 44:348-357 (Pubitemid 40316027)
36. Eksborg S, Soderhall S, Frostvik-Stolt M et al (2000) Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. Anticancer Drugs 11:237-241 (Pubitemid 30416951)
37. Kato Y, Nishimura S, Sakura N et al (2003) Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 45:74-79 (Pubitemid 36523564)
38. Wurthwein G, Klingebiel T, Krumpelmann S et al (2002) Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. Anticancer Drugs 13:101-110 (Pubitemid 34169533)
39. Davidson A, Gowing R, Lowis S et al (1997) Phase II study of 21 day schedule oral etoposide in children. New agents group of the United Kingdom children's cancer study group (UKCCSG). Eur J Cancer 33:1816-1822
40. Lowis SP, Pearson AD, Newell DR et al (1993) Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 53:4881-4889
41. Mross K, Reifke J, Bewermeier P et al (1996) The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. Ann Oncol 7:83-88 (Pubitemid 26051869)
42. Palle J, Britt-Marie F, Goran G et al (2006) Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 17:1087-1094 (Pubitemid 44454787)
43. Kushner BH, Kramer K, Cheung NK (1999) Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 17:3221-3225 (Pubitemid 29470655)
44. Simon T, Langler A, Harnischmacher U et al (2007) Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol 133:653-661 (Pubitemid 47077057)
45. Simon T, Langler A, Berthold F et al (2007) Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol 29:101-106 (Pubitemid 46213856)
46. Frost BM, Eksborg S, Bjork O et al (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329-337 (Pubitemid 34493112)
47. Hempel G, Flege S, Wurthwein G et al (2002) Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 49:133-141 (Pubitemid 34119011)
48. Palle J, Frost BM, Peterson C et al (2006) Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 17:385-392 (Pubitemid 44309980)
49. Mugishima H, Matsunaga T, Yagi K et al (2002) Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 24:94-100 (Pubitemid 34150547)
50. Vassal G, Doz F, Frappaz D et al (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852 (Pubitemid 46606240)
51. Rodriguez-Galindo C, Crews KR, Stewart CF et al (2006) Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 57:15-24
52. Bomgaars L, Kerr J, Berg S et al (2006) A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 46:50-55 (Pubitemid 41779317)
53. Levy AS, Meyers PA, Wexler LH et al (2009) Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 115:207-216
54. Gore L, Chawla S, Petrilli A et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242-247
55. Weigel BJ, Blaney SM, Reid JM et al (2007) A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children's oncology group study. Clin Cancer Res 13:1789-1793 (Pubitemid 46952947)
56. Bagatell R, Gore L, Egorin MJ et al (2007) Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783-1788 (Pubitemid 46952946)
57. Bond M, Bernstein ML, Pappo A et al (2008) A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children's oncology group study. Pediatr Blood Cancer 50:254-258
58. Marangon E, Citterio M, Sala F et al (2009) Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph + acute leukemias. Cancer Chemother Pharmacol 63:563-566
59. Pollack IF, Jakacki RI, Blaney SM et al (2007) Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report. Neuro Oncol 9:145-160 (Pubitemid 46580316)
60. Dennison JB, Jones DR, Renbarger JL et al (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563 (Pubitemid 46628594)
61. Plasschaert SL, Groninger E, Boezen M et al (2004) Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76:220-229 (Pubitemid 39221796)
62. Schaefer M, Roots I, Gerloff T (2006) In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 16:855-861
63. Filipski KK, Loos WJ, Verweij J et al (2008) Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14:3875-3880
64. Oldenburg J, Fossa SD, Ikdahl T (2008) Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 9:1521-1530
65. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23 (Pubitemid 46137553)
66. Zhang L, Plon SE, Nuchtern JG et al (2004) Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs 15:883-888
67. de Cremoux P, Jourdan-Da-Silva N, Couturier J et al (2007) Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48:311-317 (Pubitemid 46238522)
68. Renbarger JL, McCammack KC, Rouse CE et al (2008) Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 50:769-771 (Pubitemid 351354782)
69. Dennison JB, Kulanthaivel P, Barbuch RJ et al (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327 (Pubitemid 44079872)
70. Woodahl EL, Crouthamel MH, Bui T, et al. (2009) MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol
71. Yang Z, Wu D, Bui T et al (2008) A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 327:474-481
72. Oldenburg J, Kraggerud SM, Cvancarova M et al (2007) Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714 (Pubitemid 350002927)
73. del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161-174
74. Kuhne A, Kaiser R, Schirmer M et al (2007) Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics 17:505-517 (Pubitemid 46905217)
75. van Schaik RH (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11:77-98
76. Kishi S, Yang W, Boureau B et al (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67-72 (Pubitemid 38029919)
77. Sohn JW, Lee SY, Lee SJ et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137-141
78. Lal S, Sandanaraj E, Wong ZW et al (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:2045-2054
79. Gonzalez-Covarrubias V, Zhang J, Kalabus JL et al (2009) Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 37:400-407
80. Wojnowski L, Kulle B, Schirmer M et al (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762 (Pubitemid 43739516)
81. Bains OS, Karkling MJ, Grigliatti TA, et al. (2009) Two non-synonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos
82. Crouthamel MH, Wu D, Yang Z et al (2006) A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 95:2767-2777 (Pubitemid 46093183)
83. Lal S, Wong ZW, Jada SR et al (2007) Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8:567-575 (Pubitemid 46939582)
84. Mossallam GI (2006) Abdel Hamid TM, Samra MA: Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J Egypt Natl Canc Inst 18:264-273
85. Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20:163-175 (Pubitemid 43087700)
86. Araki K, Fujita K, Ando Y et al (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255-1259 (Pubitemid 44430653)
87. Cote JF, Kirzin S, Kramar A et al (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275 (Pubitemid 46944912)
88. Jada SR, Lim R, Wong CI et al (2007) Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421 C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461-1467
89. Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497-504 (Pubitemid 46905216)
90. de Jong FA, Scott-Horton TJ, Kroetz DL et al (2007) Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42-49 (Pubitemid 46050866)
91. Han JY, Lim HS, Yoo YK et al (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138-147
92. Sai K, Saito Y, Fukushima-Uesaka H et al (2008) Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 62:529-537
93. Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a children's oncology group study. J Clin Oncol 25:4622-4627 (Pubitemid 350035322)
94. Gaspar N, Sharp SY, Pacey S et al (2009) Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 69:1966-1975
95. Goetz MP, Toft D, Reid J et al (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087 (Pubitemid 46202262)
96. Guo W, Reigan P, Siegel D et al (2005) Formation of 17-allylamino- demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H: quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65:10006-10015 (Pubitemid 41541482)
97. Kelland LR, Sharp SY, Rogers PM et al (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949
98. Gardner ER, Burger H, van Schaik RH et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80:192-201 (Pubitemid 44160695)
99. Gurney H, Wong M, Balleine RL et al (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82:33-40 (Pubitemid 46944197)
100. Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926 (Pubitemid 32059164)
101. Ando Y, Ueoka H, Sugiyama T et al (2002) Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 24:111-116 (Pubitemid 34106739)
102. Carlini LE, Meropol NJ, Bever J et al (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226-1236 (Pubitemid 40175775)
103. Charasson V, Bellott R, Meynard D et al (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528-535 (Pubitemid 39601543)
104. de Jong FA, Marsh S, Mathijssen RH et al (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894 (Pubitemid 39180970)
105. Font A, Sanchez JM, Taron M et al (2003) Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Investig New Drugs 21:435-443 (Pubitemid 38124983)
106. Gagne JF, Montminy V, Belanger P et al (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617 (Pubitemid 36329379)
107. Innocenti F, Grimsley C, Das S et al (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733 (Pubitemid 36054939)
108. Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388 (Pubitemid 41103619)
109. Iyer L, Hall D, Das S et al (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582 (Pubitemid 29237332)
110. Jinno H, Tanaka-Kagawa T, Hanioka N et al (2003) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31:108-113 (Pubitemid 36735264)
111. Jinno H, Saeki M, Saito Y et al (2003) Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306:688-693 (Pubitemid 36886169)
112. Kaniwa N, Kurose K, Jinno H et al (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686 C>T (P229L) found in an African-American. Drug Metab Dispos 33:458-465 (Pubitemid 40279948)
113. Marcuello E, Altes A, Menoyo A et al (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682 (Pubitemid 39141623)
114. Mathijssen RH, Marsh S, Karlsson MO et al (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253 (Pubitemid 37086673)
115. Mathijssen RH, de Jong FA, van Schaik RH et al (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592 (Pubitemid 39534882)
116. Paoluzzi L, Singh AS, Price DK et al (2004) Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854-860 (Pubitemid 38971566)
117. Rouits E, Boisdron-Celle M, Dumont A et al (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159 (Pubitemid 39099790)
118. Sai K, Kaniwa N, Itoda M et al (2003) Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13:741-757 (Pubitemid 38429252)
119. Sai K, Saeki M, Saito Y et al (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515 (Pubitemid 38746601)
120. Soepenberg O, Dumez H, Verweij J et al (2005) Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11:1504-1511 (Pubitemid 40315233)
121. Villeneuve L, Girard H, Fortier LC et al (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128 (Pubitemid 37151897)
122. Wu MH, Chen P, Wu X et al (2004) Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics 14:595-605 (Pubitemid 39281814)
123. Zhou Q, Sparreboom A, Tan EH et al (2005) Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 59:415-424 (Pubitemid 40523885)
124. Kang J, Kamal A, Burrows FJ et al (2006) Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 26:1903-1908 (Pubitemid 43989448)
125. Jayanthan A, Fowler J, Hawkins L et al (2008) Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. J Exp Ther Oncol 7:183-193
126. Munoz M, Rosso M (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs
127. Huang F, Greer A, Hurlburt W et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161-170
128. Wallick CJ, Gamper I, Thorne M et al (2005) Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24:5606-5618 (Pubitemid 43119354)
129. Hogarty MD, Norris MD, Davis K et al (2008) ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68:9735-9745
130. Koomoa DL, Yco LP, Borsics T et al (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68:9825-9831
131. Rounbehler RJ, Li W, Hall MA et al (2009) Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69:547-553
132. Beppu K, Jaboine J, Merchant MS et al (2004) Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96:46-55 (Pubitemid 38180959)
133. Rossler J, Zambrzycka I, Lagodny J et al (2006) Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. Biochem Biophys Res Commun 342:1405-1412
134. Palmberg E, Johnsen JI, Paulsson J et al (2009) Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int J Cancer 124:1227-1234
135. Vitali R, Cesi V, Nicotra MR et al (2003) c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 106:147-152 (Pubitemid 36835164)
136. Petain A, Kattygnarath D, Azard J et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14:7102-7109
137. Van Maerken T, Speleman F, Vermeulen J et al (2006) Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66:9646-9655 (Pubitemid 44623664)
138. Ribas J, Boix J, Meijer L (2006) (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res 312:2394-2400 (Pubitemid 43959856)
139. Becker K, Marchenko ND, Maurice M et al (2007) Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ 14:1350-1360 (Pubitemid 46965264)
140. Michaelis M, Rothweiler F, Klassert D et al (2009) Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 69:416-421
141. Barbieri E, Mehta P, Chen Z et al (2006) MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 5:2358-2365 (Pubitemid 44530473)
142. Aghi M, Martuza RL (2005) Oncolytic viral therapies - the clinical experience. Oncogene 24:7802-7816 (Pubitemid 41670681)
143. Shen Y, Nemunaitis J (2006) Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13:975-992 (Pubitemid 44564734)
144. Geoerger B, van Beusechem VW, Opolon P et al (2005) Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 7:584-594 (Pubitemid 40744524)
145. Toyoda H, Yin J, Mueller S et al (2007) Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67:2857-2864 (Pubitemid 46548976)
146. Mahller YY, Williams JP, Baird WH et al (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4:e4235
147. Ino Y, Saeki Y, Fukuhara H et al (2006) Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12:643-652 (Pubitemid 43166160)
148. Mahller YY, Vaikunth SS, Ripberger MC et al (2008) Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68:1170-1179 (Pubitemid 351272236)
149. Parikh NS, Currier MA, Mahller YY et al (2005) Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 44:469-478 (Pubitemid 40614495)
150. Li H, Dutuor A, Tao L et al (2007) Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13:316-322 (Pubitemid 46121885)
151. Thomas SK, Messam CA, Spengler BA et al (2004) Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 279:27994-27999 (Pubitemid 38900069)
152. Korja M, Finne J, Salmi TT et al (2005) Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Mod Pathol 18:1599-1605 (Pubitemid 41670659)
153. Breimer DD (2008) PK/PD modelling and beyond: impact on drug development. Pharm Res 25:2720-2722
154. Zhang L, Sinha V, Forgue ST et al (2006) Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 33:369-393 (Pubitemid 44020386)
155. Derendorf H, Lesko LJ, Chaikin P et al (2000) Pharmacokinetic/ pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1399-1418
156. Miller R, Ewy W, Corrigan BW et al (2005) How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 32:185-197 (Pubitemid 41712739)
157. Rajman I (2008) PK/PD modelling and simulations: utility in drug development. Drug Discov Today 13:341-346